Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly rose Friday after topping Wall Street's first-quarter expectations. Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Medicare kickbacks alleged, Joann store closures, and more business headlines. Read the latest news and updates here.

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

Shares of Eli Lilly (NYSE: LLY) are sliding on Thursday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) gained 1% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) gained 1.9%. The pharmaceutical ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.